These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1702301)

  • 1. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.
    Durda PJ; Bacheler L; Clapham P; Jenoski AM; Leece B; Matthews TJ; McKnight A; Pomerantz R; Rayner M; Weinhold KJ
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1115-23. PubMed ID: 1702301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
    Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
    J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
    Akerblom L; Hinkula J; Broliden PA; Mäkitalo B; Fridberger T; Rosen J; Villacres-Eriksson M; Morein B; Wahren B
    AIDS; 1990 Oct; 4(10):953-60. PubMed ID: 1702001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    Fung MS; Sun CR; Gordon WL; Liou RS; Chang TW; Sun WN; Daar ES; Ho DD
    J Virol; 1992 Feb; 66(2):848-56. PubMed ID: 1370558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
    Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120.
    Ohno T; Terada M; Yoneda Y; Shea KW; Chambers RF; Stroka DM; Nakamura M; Kufe DW
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10726-9. PubMed ID: 1961739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
    J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Jan; 69(1):101-9. PubMed ID: 7527081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
    Scott CF; Silver S; Profy AT; Putney SD; Langlois A; Weinhold K; Robinson JE
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8597-601. PubMed ID: 1700435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Ho DD; Fung MS; Cao YZ; Li XL; Sun C; Chang TW; Sun NC
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8949-52. PubMed ID: 1717992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
    Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
    J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of immunoreactive, conserved regions in the external glycoprotein of the human immunodeficiency virus type 1.
    di Marzo Veronese F; Rahman R; Pal R; Boyer C; Romano J; Kalyanaraman VS; Nair BC; Gallo RC; Sarngadharan MG
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1125-32. PubMed ID: 1380259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
    Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA
    J Virol; 1995 Jan; 69(1):222-30. PubMed ID: 7527084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.